Australian Public Assessment Report for Tafamidis and ...

In the ATTR-PN studies, treatment related TEAEs showed an excess of urinary tract infection in the tafamidis group. Discontinuations due to adverse events (AEs) were more frequent in the placebo group (28.8%) than the tafamidis group (18.2% for 20 mg and 22.7% for 80 mg). ................
................